Our Commitment to You
In the end, the difference between CEDRA Corporation and many CROs comes down to one of commitment. At CEDRA, we’re committed to thorough study design, meticulous execution and painstaking reporting. We’re committed to high-efficiency, cost-effective methods and quality processes to ensure results, on time, every time. We’re committed to providing the kind of service that builds long-term relationships based on trust and consistent performance.
Here at CEDRA, we firmly believe that there are better ways to predict therapeutic and unwanted effects of novel compounds earlier in development. Further, we believe that we can provide savings in both time and money by utilizing new therapeutic tools and approaches to early drug development that expand our knowledge prior to large trials.
Many of these tools and approaches facilitate the development of compounds by defining an active dose for Phase II/III clinical trials and help sponsors learn more about biochemical processes that drive clinical effects. We provide unique information about drugs that can be accomplished more efficiently than traditional programs.
We offer access to tools, patient populations, specialized procedures and services that very few, if any, CROs can. CEDRA, in conjunction with Worldwide Clinical Trials WCT, our parent company, has been involved with the creation of numerous specialized techniques and services that are responsible for launching many successful drug development programs. If a commitment to you, your project and your research sounds like the way you’d like to do business, talk to CEDRA.